SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused…
SAN CARLOS, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a…
MONTREAL, March 08, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH)…
Posters will feature programs with best-in-class potential including ERK1/2 inhibitor ERAS-007, SHP2 inhibitor ERAS-601, and…
REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage…
Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 in Advanced Solid Tumors to…
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company…
OSLO, Norway, March 08, 2022 (GLOBE NEWSWIRE) — Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD),…
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST),…
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage…
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company…
Clinical Update from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic Melanoma…
Updated data from Phase 1 expansion cohort of ZN-c3 in uterine serous carcinoma (USC) will…
ORIC-533 oral presentation and poster presentation to highlight potential of small molecule inhibitor of CD73…
– Abstract highlights the Company’s progress in applying gene circuits to improve the cytotoxicity and…
FORT COLLINS, Colo., March 08, 2022 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (NASDAQ: STAB) (the…
– Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a…
Oral presentation to showcase NGM Bio’s in vitro and in vivo research demonstrating potential advantages…
— Recorded Third Quarter Revenue of $31.5 Million — — Myford South and Viral Vector…
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company…